A Study Assessing PG286 Ophthalmic Solution, 0.5% Compared to Its Individual Components for 28 Days

Completed · Phase 2

Conditions studied: Open Angle Glaucoma, Ocular Hypertension

In brief

In the double-masked, randomized, multi-center, active-controlled parallel study, patients will be randomized to receive either a fixed dose combination of AR-12286 and travoprost, AR-12286, or travoprost. The hypothesis is that there is no difference between each treatment arm.

Key facts

Study ID
NCT01789736
Run by
Aerie Pharmaceuticals
People needed
234
Starts
2013-02-01
Expected to finish
2013-06-01
Last updated by the study team
2014-03-17

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.